We believe science and compassion must work together to transform lives. Our website address is www.horizontherapeutics.com. We continue to anticipate the disruption could last through the first quarter of 2021. It is therefore critical for patients to maintain therapy. We also have marketing rights to PROCYSBI in Asia. 6) We market QUINSAIR in Canada. 7) Outside the United States, RAYOS is sold and marketed as LODOTRA. See "Impact of COVID-19" above for further information. 10 RAVICTI competes with older-generation nitrogen scavenger medicines. Older therapies require administration of medicine every six hours. Cystagon is PROCYSBI's primary competitor. As a result, the immune system is weakened. We estimate that there are approximately 1,600 patients with CGD in the United States. We have retained our rights to BUPHENYL in North America. We focus our promotion of RAYOS on rheumatology indications, including RA and PMR. Under these amendments, our rights to LODOTRA in Europe were transferred to Vectura. The primary endpoint for both trials will be FVC. In addition, it has the potential for subcutaneous dosing. In severe cases, respiratory muscles may be compromised. Inflammation and destruction of these glands lead to dry eye and dry mouth. There are currently no treatments approved for Sjögren's syndrome. Targeting this pathway with VIB4920 may reduce inflammation and tissue damage. We may also terminate the agreement within nine months written notice to Roche. If not otherwise invalidated, those patents expire between 2023 and 2030. ACTIMMUNE We have licenses to U.S. patents covering ACTIMMUNE. The FDA does not regulate the behavior of physicians in their choice of treatments. This period may be extended by two further months. France however has a statutory regime similar to the U.S. Sunshine Act. Other legislative changes have also been proposed and adopted since the ACA was enacted. These benefits are paid at 100 percent salary. We also provide equal opportunity in employment to all employees and applicants. 49 Our clinical trials may be affected by COVID-19. It could also lead to an increase in the complexity and cost of tax compliance. Any of these could have a material adverse effect on our business and financial results. Failure can occur at any time during the clinical trial process. A transfer of our ordinary shares may be subject to Irish stamp duty. Litigation may be necessary to defend against these claims.